Wet Age-related Macular Degeneration Market
As per DelveInsight Business Research LLP analysis, of all the Wet Age-related Macular Degeneration emerging therapies, the most anticipated product to get launched is Abicipar Pegol, a lead candidate of Allergan.
Several other emerging #therapies such as GB-102 by Graybug Vision, Inc., ALK4290 by Alkahest, Inc., Vorolanib by EyePoint Pharmaceuticals, IBI 302 by Innovent Biologics（信达生物制药）and FYB201 by Bbioeq GmbH are also expected to shift the Wet Age-related macular degeneration landscape positively.
For more details visit: https://www.delveinsight.com/blog/wet-age-related-macular-degeneration-treatment-market/
#market #marketresearch #pharma #biotech #lifescience #medical #healthcare #maculardegeneration
Wuhan Coronavirus: A global emergency
Despite strict travel guidelines, and restricted movement to and from- China, the caseloads of Wuhan Coronavirus are increasing at an alarming rate, with suspected cases now been confirmed, and a cloud of uncertainty on the number of deaths it may cause, looming. With the infected cases totalling to 45,168, and the deaths around 1,115- surpassing the death rate reported at the time of Severe acute respiratory syndrome (#SARS)- the novel Coronavirus has now come to know as Coronavirus disease 2019 (COVID-19). Therapies, which Pharma companies are reportedly working on, and have the potential to cure the coronavirus epidemic are: Noravax MERS, Invio’s INO-4700, Biocryst’s Galidesivir, AbbVie’s Lopinavir HIV inhibitor, Regeneron’s REGN3048-3051. To read more about coronavirus, visit: https://www.delveinsight.com/blog/coronavirus/ or https://www.delveinsight.com/blog/coronavirus-2019-ncov-is-now-covid-19/
Wet Age-Related Macular Degeneration
As per the BrightFocus Foundation, nearly 11 million Americans are living with one or other type of Age-Related Macular degeneration (AMD). With approximately 200,000 diagnoses of new cases of Wet Age-Related Macular Degenerationeach year in the U.S., Wet Age-Related Macular Degeneration, also known as neovascular or exudative Wet Age-Related Macular D
egeneration, affects around 1.1 million of the Americans.
Several emerging therapies such as Abicipar Pegol by Allergan, Brolucizumab by Novartis, GB-102 by Graybug Vision, Inc., ALK4290 by Alkahest, Inc., Vorolanib by EyePoint Pharmaceuticals, and FYB201 by Bioeq GmbH are expected to shift the Wet Age-related macular degeneration landscape positively.
Visit to read more: https://www.delveinsight.com/blog/wet-age-related-macular-degeneration/
#pharma #biotech #healthcare #medical #macular #market #marketresearch #lifescience #health
Joined Feb 2020
